Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Economic Evaluation of Heart Failure Management in Colombian Clinics (EconoHeart)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01084564
First received: March 9, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted

March 9, 2010
March 9, 2010
January 2008
June 2008   (final data collection date for primary outcome measure)
  • To determine cost-effectiveness of Heart Failure management in 3 Heart-specialized clinics in Bogotá Colombia [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy (SMART) when compared with its competitive alternatives [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Economic Evaluation of Heart Failure Management in Colombian Clinics
Economic Evaluation of Heart Failure Management in Colombian Clinics

Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Moderate to severe uncontrolled asthma.

  • Heart Failure
  • Asthma
Not Provided
1
moderate to severe uncontrolled asthma
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
June 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Asthma moderate to severe.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01084564
NIS-CCO-ATA-2007/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Study Director: Rodolfo Dennis, M.D. Pontificia Universidad Javeriana
Principal Investigator: MARÍA XIMENA ROJAS, M.D. Pontificia Universidad Javeriana
AstraZeneca
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP